BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 169 filers reported holding BRIDGEBIO PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.33 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,957 | +53.3% | 643 | 0.0% | 0.00% | – |
| Q2 2023 | $11,061 | +3.8% | 643 | 0.0% | 0.00% | – |
| Q1 2023 | $10,660 | +84.3% | 643 | -15.3% | 0.00% | – |
| Q4 2022 | $5,783 | -17.4% | 759 | +4.3% | 0.00% | – |
| Q3 2022 | $7,000 | 0.0% | 728 | 0.0% | 0.00% | – |
| Q2 2022 | $7,000 | +133.3% | 728 | +225.0% | 0.00% | – |
| Q1 2022 | $3,000 | +200.0% | 224 | +173.2% | 0.00% | – |
| Q4 2021 | $1,000 | -99.6% | 82 | -98.5% | 0.00% | – |
| Q3 2021 | $249,000 | -21.2% | 5,338 | +2.8% | 0.00% | – |
| Q2 2021 | $316,000 | -15.1% | 5,194 | -13.8% | 0.00% | – |
| Q1 2021 | $372,000 | +24.4% | 6,028 | +43.7% | 0.00% | – |
| Q4 2020 | $299,000 | +29800.0% | 4,196 | +11555.6% | 0.00% | – |
| Q3 2020 | $1,000 | 0.0% | 36 | -12.2% | 0.00% | – |
| Q2 2020 | $1,000 | – | 41 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |